Currently, there are no approved topicals for the treatment of prurigo nodularis. According to the presenter, ruxolitinib cream 1.5% could become the first. ORLANDO — Ruxolitinib cream 1.5% ...

Opens in a new tab or window ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of starting topical ruxolitinib (Opzelura ...

Incyte INCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ruxolitinib cream 1.5% in adults with prurigo nodularis (PN). The data ...

Given the late-breaking data on topical ruxolitinib's effectiveness in prurigo nodularis and its rapid itch relief, how do you foresee this impacting treatment paradigms for chronic pruritic ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Galderma’s Nemluvio (nemolizumab) to treat both atopic dermatitis and prurigo nodularis. The UK regulator has specifically ...

“We’re bringing impactful new science to this year’s AAD meeting, with new data on Nemluvio – our treatment for prurigo nodularis and atopic dermatitis – and the latest from our ...

March 2 (UPI) --Patients whose autoimmune disorders such as lupus were initially dismissed by doctors as psychosomatic show long-lasting adverse impacts on their mental health and trust in ...

"We look forward to sharing new data for ruxolitinib cream (Opzelura ®) across multiple indications, including prurigo nodularis, and axatilimab (Niktimvo™) in patients with dermatologic ...

Chronic prurigo, also known as prurigo nodularis, is a disease characterized by extremely itchy lesions. Due to this persistent itch, patients with this disease tend to experience psychological ...